Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics
RCUS Price/Volume Stats
| Current price | $15.43 | 52-week high | $25.47 |
| Prev. close | $15.50 | 52-week low | $12.95 |
| Day low | $14.71 | Volume | 524,000 |
| Day high | $15.85 | Avg. volume | 806,906 |
| 50-day MA | $17.45 | Dividend yield | N/A |
| 200-day MA | $17.60 | Market Cap | 1.40B |
RCUS Stock Price Chart Interactive Chart >
Arcus Biosciences, Inc. (RCUS) Company Bio
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.
Latest RCUS News From Around the Web
Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.
Arcus Biosciences Announces New Employment Inducement GrantsHAYWARD, Calif., December 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and |
We Think Arcus Biosciences (NYSE:RCUS) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer StudyExelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC. |
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis |
RCUS Price Returns
| 1-mo | -7.33% |
| 3-mo | 1.98% |
| 6-mo | 7.68% |
| 1-year | -14.23% |
| 3-year | -56.75% |
| 5-year | 41.82% |
| YTD | -19.21% |
| 2023 | -7.64% |
| 2022 | -48.90% |
| 2021 | 55.89% |
| 2020 | 157.03% |
| 2019 | -6.22% |
Continue Researching RCUS
Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...